Home/Investors/Deep Track Capital

Deep Track Capital

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$887.5M

Focus Areas

5

Top Stage

Phase 2

Investment Focus

Schizophrenia Bipolar Depression Neuropsychiatric Diseases Autoimmune Diseases Inflammatory Diseases

Portfolio Companies

Company	Stage	Valuation	Focus
LB Pharmaceuticals	Phase 2	$887.5M	Schizophrenia, Bipolar Depression
Sonoma Biotherapeutics	Phase 1	—	Autoimmune Diseases, Inflammatory Diseases

Frequent Co-Investors

Frazier Life Sciences1 shared ARCH Venture Partners1 shared Alexandria Venture Investments1 shared 8VC1 shared Vertex Ventures HC1 shared Lilly Asia Ventures1 shared Casdin Capital1 shared Google Ventures1 shared